Simcere Pharmaceutical's (HKG:2096) attributable profit is seen to jump 0.4% to 4.6% to between 718 million yuan and 748 million yuan in 2024 from 715 million yuan in 2023, according to a Friday filing with the Hong Kong Stock Exchange.
Revenue is also forecast to inch up 0.2% to 0.6% to between 6.62 billion yuan and 6.65 billion yuan.
The drug company plans to release fiscal 2024 results in late March.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。